Study of Updated COVID-19 Vaccines for High-Risk Groups
Part of Infections, Lungs & breathing clinical trials.
This trial tests updated COVID-19 vaccines designed to better protect against current variants. It's for people who have already been vaccinated and are at higher risk for severe COVID-19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received at least one COVID-19 vaccine.
- Adults 65 or older, or anyone 6 months and older with at least one risk factor for severe COVID-19 (like heart disease, diabetes, or weakened immune system).
- You cannot have had COVID-19 within the last 6 months.
- You cannot have had a COVID-19 vaccine within the last 6 months.
- You must not have a severe allergy to mRNA vaccines (like anaphylaxis).
- Women who can become pregnant must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different ways of giving the covid-19 vaccine to see which one works better. It may help improve how vaccines are delivered in the future.
This study tests an updated mRNA COVID-19 vaccine to see how well it boosts immunity and how safe it is. It may help protect you from severe COVID-19 if you are older or have certain health conditions.
This study tests a new mRNA vaccine (called mRNA-1283) to protect against COVID-19 in children from 6 months to under 12 years old. It aims to see if the vaccine is safe and produces a good immune response.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
This trial is testing whether a new mRNA vaccine that targets both seasonal flu and COVID-19 is safe and creates a strong immune response. It may offer an easier way to protect against two illnesses with one shot.
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
Hear when a new SARS CoV-2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.